MCMinghui Cai

Minghui Cai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Minghui Cai has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Chen

    Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China

    1 shared publication
  • Jianchen Zheng

    School of Basic Medicine and Forensic Medicine, Hangzhou Medical College, Hangzhou, China

    1 shared publication
  • Jiasheng Xu

    Department of Radiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China

    1 shared publication
  • Jincheng Lai

    School of Basic Medicine and Forensic Medicine, Hangzhou Medical College, Hangzhou, China

    1 shared publication
  • Lifei Meng

    Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China

    1 shared publication
  • Lingwei Zhu

    Department of Radiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China

    1 shared publication

Latest Publications

  • Open Access

    MRC1⁺ macrophages and endothelial PTPRM signalling characterize a microvascular invasion–associated tumor ecosystem in hepatocellular carcinoma

    by Jincheng Lai, Jianchen Zheng, Yuyi Feng, Lingwei Zhu, Ying Chen, Shijie Lou, Jiasheng Xu, Minghui Cai, Wenbin Ji

  • Open Access

    Single-cell transcriptomic analysis reveals cellular and molecular changes in EGFR-positive lung adenocarcinoma before and after Furmonertinib treatment

    by Jian Chen, Minghui Cai, Lifei Meng, Ze Hong, Wentao Hu

    Background: Lung adenocarcinoma (LUAD) frequently harbors activating mutations in the epidermal growth factor receptor (EGFR), making EGFR tyrosine kinase inhibitors (EGFR-TKIs) a critical component of targeted therapy. Although third-generation EGFR-TKIs, such as Furmonertinib, have improved outcomes for patients with EGFR-mutant LUAD, drug resistance and tumor adaptation remain major challenges. The cellular and molecular mechanisms underlying response and adaptation to Furmonertinib, particularly within the tumor microenvironment (TME), are not fully understood. Methods: We performed single-cell RNA sequencing on tumor and paired paracancerous tissues from EGFR-positive LUAD patients before and after Furmonertinib treatment, integrating both public and in-house datasets. We systematically analyzed changes in cellular composition, gene expression profiles, pathway enrichment, and ligand–receptor-mediated cell–cell communication. Results: Furmonertinib treatment led to a marked reduction in tumor cell proportion and profound remodeling of the TME. There was an increase in T cell infiltration, particularly CD4 + T cells, and a decrease in exhausted CD8 + T cells, indicating a shift toward a less immunosuppressive microenvironment. Cancer-associated fibroblasts and monocytes were also enriched post-treatment. Tumor cells exhibited increased EGFR expression, along with transcriptomic reprogramming characterized by upregulation of signaling, immune, and differentiation pathways, and downregulation of metabolic and protein synthesis genes. Cell–cell communication analysis revealed attenuation of immunosuppressive signaling (such as MIF axis) and enhancement of alternative ligand–receptor interactions, including LAMC1- and EGFR-related pathways. Conclusions: Our integrative single-cell analysis reveals that Furmonertinib therapy induces significant cellular and molecular changes in EGFR-positive LUAD, including TME remodeling, transcriptomic adaptation, and reprogramming of intercellular communication networks. These findings provide insight into the mechanisms of Furmonertinib response and resistance, and may inform strategies to optimize EGFR-TKI therapy.